BY ANJA HAUGE
-
New GN Hearing president wants to build on strong foundations, not “turning everything upside down”
Peter Justesen has taken over as president of GN’s Hearing division.
-
US drugmakers betting big on China to secure blockbuster medicines
In 2025, 14 permit contracts have actually been authorized thus far, with a prospective worth of USD 18.3 bn.
-
US health secretary announces stricter rules for pharmaceutical advertising
This indicates that policies will transform for a market that has a complete worth of about USD 11bn.
-
Bavarian Nordic sells priority review voucher to US healthcare system USD 160m
The firm anticipates the deal to have an effect on Bavarian Nordic’s operating profits.
-
Pfizer to reconsider its position in the EU after new proposal: “It does not raise interest”
It is fretting that European priests are recommending to reduce the duration of market defense for brand-new medication, claims Pfizer’s public relations principal in Denmark…
-
Demant acquires German hearing aid retailer KIND Group
Danish listening device team acquires German store in an offer worth EUR 700m.
-
Demant still eyeing acquisitions in 2025
A lot more firms might be contributed to the layer throughout the year, according to the chief executive officer after Demant acquired a German firm for EUR 700m.
-
Demant CEO: KIND acquisition will lead to guidance upgrade
The Danish firm has actually essentially preserved its 2025 expectation after acquiring the seller Wednesday, however chief executive officer claims an advice upgrade will certainl…
-
Two RSV vaccines receive expanded approvals
Injections from GSK and Moderna are given extensive usage authorizations in both Europe and the United States.
-
Bavarian Nordic testing AI for vaccine production – but won’t take the lead
While various other injection firms are spending greatly in AI, Bavarian Nordic is taking one action at once.
